Historically, erythropoietin has been known as the primary hematopoietic growth factor which regulates cellular proliferation and differentiation of the erythroid lineage, leading to frequent usage of erythropoietin stimulating agents (ESAs) for patients with chronic kidney disease (CKD) and anemia associated with cancer [2]. This evidence concerns the gene EPO and anemia.